



Contents lists available at ScienceDirect

Vaccine

journal homepage: [www.elsevier.com/locate/vaccine](http://www.elsevier.com/locate/vaccine)

## Review

## Establishment of specific pathogen-free macaque colonies in Tsukuba Primate Research Center of Japan for AIDS research

Yasuhiro Yasutomi<sup>a, b, \*</sup><sup>a</sup> Laboratory of Immunoregulation and Vaccine Research, Tsukuba Primate Research Center, National Institute of Biomedical Innovation, Tsukuba, Ibaraki 305-0843, Japan<sup>b</sup> Department of Immunoregulation, Mie University Graduate School of Medicine, Mie 514-8507, Japan

## ARTICLE INFO

## Article history:

Received 9 April 2009

Received in revised form 13 August 2009

Accepted 18 September 2009

## Keywords:

Macaque

SPF

Virus

## ABSTRACT

Cynomolgus monkeys have been maintained in indoor facilities as closed colony monkeys in Tsukuba Primate Research Center in Japan since 1978. Several microorganisms, including bacteria, parasites and viruses, were eliminated from the cynomolgus monkeys in this colony of TPRC. Various kinds of viruses (B virus, measles virus, simian varicella virus, simian immunodeficiency virus, simian T cell leukemia virus, simian D type retrovirus, simian cytomegalovirus, simian Epstein-Barr virus, and simian foamy virus), bacteria (*Shigella*, *Salmonella* and *Mycobacteria spp.*) and intestinal helminth were chosen as target microorganisms to establish a specific pathogen-free (SPF) colony. Except for a few pathogens (simian D type retrovirus, simian Epstein-Barr virus, and simian foamy virus), selected pathogens were completely eliminated from all monkeys in TPRC. In this review, the history of establishment of SPF cynomolgus monkey colonies in Japan is described.

© 2009 Elsevier Ltd. All rights reserved.

## Contents

1. Introduction.....	B75
1.1. First term (1978–1882).....	B76
1.2. Second and third terms (1983–1994).....	B76
1.3. Fourth and fifth terms to present (1995–2009).....	B77
2. Conclusions.....	B77
Acknowledgements.....	B77
Conflict of interest statement.....	B77
References.....	B77

### 1. Introduction

Nonhuman primates are critical resources for biomedical research. Macaque monkeys are one of the key nonhuman primate models that share nearly all characteristics with humans. Conditions of experimental animals are very important for biomedical experiments. The animals should not be infected with microorganisms because microorganism infection may affect results. Moreover, some pathogens are likely to harm not only monkeys but also humans in experiments involving macaques. For these reasons, there is a need for specific pathogen-free (SPF) macaque colonies for

research purposes, biohazard avoidance and maintenance of health levels in established colonies (Table 1).

Tsukuba Primate Research Center (TPRC) in Japan has a large-scale breeding colony of experimental cynomolgus monkeys (approximately 1500 monkeys), which play a significant role in the development of pharmaceutical products and medical technologies. The center is the forefront facility in Japan that both supplies laboratory-bred monkeys, mainly cynomolgus monkeys, and performs medical research. Cynomolgus monkeys have been maintained in indoor facilities as closed colony monkeys in TPRC since 1978 [1]. In addition to quality control, supply, research resource development, and basic technology development involving the experimental monkeys, evaluation of state-of-the-art medical technology, evaluation of the efficacy of new drugs and safety assessments are also performed using the monkeys. The establishment of SPF macaques is therefore necessary in TPRC.

\* Laboratory of Immunoregulation and Vaccine Research, Tsukuba Primate Research Center, National Institute of Biomedical Innovation, 1-1 Hachimandai, Tsukuba, Ibaraki 305-0843, Japan. Tel.: +81 29 837 2073; fax: +81 29 837 2053.  
E-mail addresses: [yasutomi@nibio.go.jp](mailto:yasutomi@nibio.go.jp), [yasutomi@doc.medic.mie-u.ac.jp](mailto:yasutomi@doc.medic.mie-u.ac.jp).

**Table 1**  
History of establishment of SPF cynomolgus monkeys in TPRC.

Year	Target microorganism	Complete elimination from TPRC
1978–1982	BV, MV, <i>Shigella</i> , <i>Salmonella</i> , <i>Mycobacteria</i> , helminth	MV, <i>Shigella</i> , <i>Salmonella</i> , <i>Mycobacteria</i> ,
1983–1994	BV, SVV, SIV, STLV-1, SRV/D helminth	SIV, STLV-1, helminth
1995–2004	BV, SVV, SRV/D,	BV, SVV,
2004–Present	SRV/D (73%) <sup>a</sup> , LCV (50%) <sup>a</sup> , SFV (31%) <sup>a</sup>	CMV

<sup>a</sup> Infection rate of all cynomolgus monkeys in TPRC at present.

The cynomolgus monkeys in TPRC were obtained from Indonesia, Malaysia and Philippines [1]. The monkeys have been bred as pure blood of each origin without interbreed crossing. These pure blood monkeys should be important for comparison of various genetic effects in biological studies including vaccine development. The establishment of SPF colonies in TPRC is also important for this reason. These three pure blood colonies and one mixed blood colony each consist of approximately 100 SPF cynomolgus monkeys. In this review, attempts to establish SPF macaque colonies for advanced biomedical research are reported.

#### 1.1. First term (1978–1882)

Several kinds of microorganisms were chosen for elimination from colony monkeys. Two viruses (B virus and measles virus), three species of bacteria (*Shigella*, *Salmonella* and *Mycobacteria spp.*) and intestinal helminths were selected as the first target pathogens for elimination in macaque colonies. B virus (BV, *Cercopithecine herpesvirus 1*) is an alphaherpesvirus that naturally infects macaque monkeys. In macaques, the virus typically causes a self-limiting disease similar to herpes simplex virus disease in humans [2]. In surprising contrast, BV infection in humans has resulted in the death of 80% of individuals [2]. Therefore, BV was firstly chosen as an SPF target pathogen for prevention of biohazard risks by this virus. The BV infections were detected by BV-specific antibody (Ab) response in sera using an ELISA system (BioReliance Co., USA). Prevention of the spread of BV in the macaque colony was carried out by early weaning of babies from mothers. Infection of the virus in plasma of the prematurely weaned monkeys was confirmed by a BV-specific Ab several times at intervals of 3–6 months. Measles, caused by measles virus (MV) infection, remains a major cause of infant mortality despite the availability of a safe and effective live attenuated virus vaccine. MV-free cynomolgus monkeys are required, since one of the purposes to supply cynomolgus monkeys in TPRC is certification tests for human measles vaccine. MV infection was examined in all monkeys by detection of specific Ab reaction in sera by ELISA and MV antigen (Ag) detected by RT-PCR. Although most of the cynomolgus monkeys from Asia were infected with MV, asymptomatic monkeys with MV excretion in plasma, urine and other biological fluid were not reproduced in TPRC. The MV-infected monkeys were eliminated by this breeding program. Two species of bacteria, *Salmonella* and *Shigella spp.*, were detected by cultivation of rectal or fecal swab samples. Monkeys having these bacteria received drug treatment (200 mg of sulfamethoxazole and 40 mg of trimethoprim once a day for 3 days by oral administration even to *Salmonella*, 200 mg of fosfomycin once a day for 3 days by oral administration even to *Shigella*) if they showed no clinical symptoms of infection with these bacteria. Infection with *Mycobacteria spp.* responsible for tuberculosis was examined by tuberculin (TB) skin tests, and monkeys with positive results of TB skin tests were eliminated. Infection with MV, *Salmonella*, *Shigella* or *Mycobacteria spp.* has not been detected in any monkeys in TPRC since 1982. Cynomolgus monkeys excreting helminth eggs in feces were given anthelmintics

(ivermectin 200 µg/kg s.c twice for 2 weeks interval; metronidazol 40 mg/kg once a day for 5 days by oral administration; thiabendazole 50 mg/kg once a day for 3 days by oral administration and mebendazole 20 mg/kg once a day for 3 days by oral administration).

#### 1.2. Second and third terms (1983–1994)

In addition to targeting BV and helminths for elimination from TPRC, simian immunodeficiency virus (SIV), simian T cell leukemia virus (STLV), simian D type retrovirus (SRV/D) and simian varicella virus (SVV) were newly targeted to establish SPF monkey colonies in 1983–1994. Although an AIDS model induced by SIV is very useful for AIDS studies, SIV is not present in macaques from Asia unless they have been experimentally exposed. In fact, natural infection with SIV was not seen in any of the monkeys in TPRC examined by ELISA for detection of SIV-specific Ab in sera. STLV is widely present in all New and Old World primate species. The incidence of STLV infection in most natural simian populations is 5–40%, but it can be much higher in wild monkeys [3,4]. STLV infection was detected in 11.7% of the monkeys in TPRC by IFA using MT-1 cells [5]. These monkeys were eliminated from TPRC over a period of several years. SVV is an alphaherpesvirus that causes varicella in Old World monkeys and establishes latent infection in ganglionic neurons [6]. Outbreaks in many animal facilities have been reported [7]. An outbreak of SVV infection occurred in TPRC during the period from November 1989 to April 1990. Varicella developed in almost 100 monkeys, and 67% of those monkeys died. The rate of infection with SVV in TPRC was 12.9% in 1990. SVV infection can usually be detected by SVV-specific Abs, even in asymptomatic monkeys, and SVV-infected monkeys were eliminated from TPRC in 2000. Attention must be paid to SRV/D both for its risk to macaque colony health and its negative effects on biomedical research. Monkeys infected with SRV/D eventually show symptoms that might be caused by SRV/D infection, such as diarrhea, weight loss and anemia, due to activation attributable to changing conditions of the individual [8–11]. This virus can be transmitted horizontally, vertically or sexually by symptomatic or asymptomatic animals. Moreover, some SRV/D-infected monkeys can become viremic yet remain Ab-negative, allowing infection to escape detection by routine Ab screening [12]. A new subtype of SRV/D, named SRV/D-T, was detected in the colony in TPRC in 2005 [13]. Certain monkeys were found to have plasma viremia of this subtype and did not develop any specific Abs to SRV/D-T. Cynomolgus monkeys in the colony showing SRV/D-T viremia secreted the virus in saliva, urine and feces, and the viruses secreted from these monkeys were thought to be a potential cause of horizontal infections of SRV/D-T. Moreover, there was a high rate of transmission of SRV/D-T infection between mothers and infants in TPRC. Screening for this virus infection was done by detection of both Ab (Western blot analysis) and virus (RT-PCR) in plasma [14]. STLV was completely eliminated from TPRC during the second and third terms.

### 1.3. Fourth and fifth terms to present (1995–2009)

Monkey infected with BV and SVV were completely eliminated from TPRC in the late 90s. Three viruses, simian cytomegalovirus (CMV), simian Epstein-Barr virus (EBV, simian lymphocryptovirus (LCV)) and simian foamy virus (SFV), were added as target viruses in a new plan in 1995 to establish SPF monkey colonies. Simian CMV infections have been reported in various species of monkeys, including macaques [15]. This virus is readily transmitted in oral secretions, breast milk and urine [16], and 3% of adult monkeys in TPRC were infected with the virus. CMV infection was detected by IFA or an ELISA system using CMV Ag. Simian EBV has also been detected in several species of Old World and New World primates [17]. This virus is also readily transmitted, and serological surveys indicated that about 90% of adult cynomolgus monkeys in TPRC were infected. Detection of EBV infection was usually done by using commercial available human IFA kit. Infection with these two viruses, CMV and EBV, in macaques are opportunistic infections. Infection with the other virus, SFV, also does not seem to cause disease in nonhuman primates as natural hosts [18]. Humans can be infected with SFV, although the number of known SFV infection cases in humans is small [19]. SFV infection was detected by IFA using SFV Ag. Monkeys infected with SFV are fraught with hazards to workers in a primate center. The rate of infection with SFV in adult monkeys in TPRC was 80%. Detection of SFV was done by Ab response in sera using ELISA. Prevention of the spread of these three viruses, CMV, LCV and SFV, was performed by artificial nursing with feeding formula for baby monkeys that had been removed from their mothers immediately after birth. CMV infection in monkeys has not been detected in TPRC since 2005.

## 2. Conclusions

SPF nonhuman primate colonies are required for biomedical research with several beneficial effects such as animal health and occupational safety. High quality of laboratory animals is also required for advanced biomedical studies including vaccine research and development. Infectious agents frequently affect the results of animal experiments. The history of establishment of SPF cynomolgus monkeys in TPRC in Japan for evaluation of state-of-the-art medical technology, evaluation of the efficacy of new drugs and new vaccines, and safety assessments has been described in this review.

## Acknowledgements

The author would like to thank all workers in TPRC since 1978 for establishing SPF macaque colonies in Japan.

This study was supported by grants from the Ministry of Health, Labor and Welfare of Japan and the Ministry of Education, Culture, Sports, Science and Technology of Japan.

## Conflict of interest statement

The author states that they have no conflict of interest.

## References

- [1] Honjo S. The Japanese Tsukuba Primate Center for Medical Science (TPC): an outline. *J Med Primatol* 1985;14:75–89.
- [2] Whitley RJ, Hillard J. Cercopithecine herpes virus (B virus). In: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, et al., editors. *Fields virology*, vol. 2, 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2007. p. 2889–903.
- [3] Richards AL, Girdl A, Iskandari D, Pamgukas J, Sle A, Rosen L, et al. Simian T lymphotropic virus type I infection among wild-caught Indonesian pig-tailed macaques (*Macaque nemestrina*). *J AIDS Hum Retroviro* 1998;19:542–5.
- [4] Schillaci M, Jones-Engel L, Engel G, Paramastri Y, Iskandar E, Willson B, et al. Prevalence of enzootic simian viruses among urban performance monkeys in Indonesia. *Trop Med Int Health* 2005;10:1305–14.
- [5] Hayami M, Komuro A, Nozawa K, Shotake T, Ishikawa K, Yamamoto K, et al. Prevalence of antibody to adult T-cell leukemia virus-associated antigens (ATLA) in Japanese monkeys and other non-human primates. *Int J Cancer* 1984;33:179–83.
- [6] Gray WL, Mullis L, Soike KF. Viral gene expression during acute simian varicella virus infection. *J Virol* 2002;83:841–6.
- [7] Gray WL. Simian varicella: a model for human varicella-zoster virus infections. *Rev Med Virol* 2004;14:363–81.
- [8] Daniel MD, Norval KW, Letvin NL, Hunt RD, Sehgal PK, Desrosiers RC. A new type D retrovirus isolated from macaques with an immunodeficiency syndrome. *Science* 1984;223:602–5.
- [9] Marx PA, Maul DH, Osborn KG, Lerche NW, Moody P, Lowenstein LJ, et al. Simian AIDS: isolation of a type D retrovirus and transmission of the disease. *Science* 1984;223:1083–6.
- [10] Lerche NW, Osborn KG. Simian retrovirus infections: potential confounding variables in primate toxicology studies. *Toxicol Pathol* 2003;31(Suppl.):103–10.
- [11] Guzman RE, Kerlin RL, Zimmerman TE. Histologic lesions in cynomolgus monkeys (*Macaca fascicularis*) naturally infected with simian retrovirus type D: comparison of seropositive, virus-positive, and uninfected animals. *Toxicol Pathol* 1999;27:672–7.
- [12] Kwng HS, Pederson NC, Lerche NW, Osborn KG, Marx PA, Gardner MB. Viremia, antigenemia and serum antibodies in rhesus macaques infected with simian retrovirus type I1 and their relationship to disease course. *Lab Invest* 1987;56:591–7.
- [13] Hara M, Sata T, Kikuchi T, Nakajima N, Uda A, Fujimoto K, et al. Isolation and characterization of new simian retrovirus type D subtype from monkeys at the Tsukuba Primate Center, Japan. *Microbes Infect* 2005;7:126–31.
- [14] Hara M, Kikuchi T, Ono F, Takano J, Ageyama N, Fujimoto K, et al. Survey of captive cynomolgus macaques colonies for SRV/D infection using polymerase chain reaction assays. *Comp Med* 2005;55:145–9.
- [15] Elkington R, Shouskry NH, Walker S, Crough T, Fazou C, Kaur A, et al. Cross-reactive recognition of human and primate cytomegalovirus sequences by human CD4 cytotoxic T lymphocytes for glycoprotein B and H. *Eur J Immunol* 2004;34:3216–26.
- [16] Barry PA, Loxkridge KM, Salamat S, Tinling SP, Yue Y, Zhou SS, et al. Non-human primate models of intrauterine cytomegalovirus infection. *ILAR J* 2006;47:49–64.
- [17] Cho Y-G, Ramer J, Rivaller P, Quink C, Garber RL, Beler DR, et al. An Epstein-Barr-related herpesvirus from marmoset lymphomas. *Proc Natl Acad Sci USA* 2001;98:1224–9.
- [18] Linial ML. Foamy viruses. In: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, et al., editors. *Fields virology*. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2007. p. 2245–63.
- [19] Jones-Engel L, May CC, Engel GA, Steinkraus KA, Schillaci MA, Fuentes A, et al. Diverse contexts of zoonotic transmission of simian foamy viruses in Asia. *Emerg Infect Dis* 2008;14:1200–8.

# Simian Betaretrovirus Infection in a Colony of Cynomolgus Monkeys (*Macaca fascicularis*)

Koji Fujimoto,<sup>1,2\*</sup> Jun-ichiro Takano,<sup>1,2</sup> Toyoko Narita,<sup>1</sup> Koji Hanari,<sup>1</sup> Nobuhiro Shimozawa,<sup>2</sup> Tadashi Sankai,<sup>2</sup> Takashi Yosida,<sup>2</sup> Keiji Terao,<sup>2</sup> Takeshi Kurata,<sup>1</sup> and Yasuhiro Yasutomi<sup>2</sup>

Of the 419 laboratory-bred cynomolgus macaques (*Macaca fascicularis*) in a breeding colony at our institution, 397 (95%) exhibited antibodies or viral RNA (or both) specific for simian betaretrovirus (SRV) in plasma. Pregnant monkeys ( $n = 95$ ) and their offspring were tested to evaluate maternal–infant infection with SRV. At parturition, the first group of pregnant monkeys ( $n = 76$ ) was antibody-positive but RNA-negative, the second group ( $n = 14$  monkeys) was positive for both antibody and RNA, and the last group ( $n = 5$ ) was antibody-negative but RNA-positive. None of the offspring delivered from the 76 antibody-positive/RNA-negative mothers exhibited viremia at birth. Eight of the offspring (including two newborns delivered by caesarian section) from the 14 dually positive mothers exhibited SRV viremia, whereas the remaining 6 newborns from this group were not viremic. All of the offspring (including 2 newborns delivered by caesarian section) of the 5 antibody-negative/RNA-positive mothers exhibited viremia at birth. One neonatal monkey delivered by CS and two naturally delivered monkeys that were viremic at birth remained viremic at 1 to 6 mo of age and lacked SRV antibodies at weaning. Family analysis of 2 viremic mothers revealed that all 7 of their offspring exhibited SRV viremia, 6 of which were also antibody-negative. The present study demonstrates the occurrence of transplacental infection of SRV in viremic dams and infection of SRV in utero to induce immune tolerance in infant monkeys.

**Abbreviation:** SRV, simian betaretrovirus.

Although simian betaretrovirus (SRV) causes symptoms of immunodeficiency, including anemia, tumors, and persistent refractory diarrhea, in some infected macaques,<sup>1,7,10</sup> most infected monkeys exhibit few or no clinical signs.<sup>2</sup> Macaques free of SRV are important in many types of experiments to avoid associated immunologic and virologic effects. Establishing an SRV-free breeding colony is paramount for a steady supply of appropriate monkeys for various experiments.<sup>8</sup>

We previously reported that SRV-T, a novel subtype of SRV, was found in the cynomolgus colony of our institution.<sup>3</sup> Approximately 20% of the colony monkeys tested in 2005 were viremic and shed SRV-T virus in saliva, urine, and feces.<sup>4,5</sup> The viruses shed by these monkeys are a potential source of horizontal SRV-T infection, as occurred in a rhesus monkey colony.<sup>6,7</sup> In the present study, we investigated the actual prevalence and transmission of SRV in the closed cynomolgus colony through several generations, to prevent the spread of the virus and to establish an SRV-free colony.

## Materials and Methods

**Animals.** The Tsukuba Primate Research Center (Tsukuba, Japan) maintains approximately 1500 cynomolgus monkeys as a breeding and rearing colony and has been maintained as a closed colony for 30 y. All adult monkeys are kept in single cages. Pregnant monkeys are produced by timed mating system in which

a female monkey is placed into a male monkey's cage for 3 d; pregnancy is confirmed by ultrasonography 5 wk after mating.

Dams nurse their offspring until weaning at approximately 6 mo. Weaned infants are paired with infants of similar size. Artificial nursing is performed when the dams do not exhibit appropriate nursing behavior.

The housing and care procedures of this study were approved by the Animal Welfare and Animal Care Committee of Tsukuba Primate Research Center of the National Institute of Biomedical Innovation.

**Samples.** Blood samples were collected from 419 breeders (female, 364; male, 55). All of these monkeys were born at Tsukuba Primate Research Center and are the second and third generations from the founder monkeys, which originated from the Philippines, Malaysia and Indonesia.

We selected 95 pregnant monkeys that exhibited SRV-specific antibodies by Western blotting or the virus as detected by RT-PCR (or both) as the subjects of the study. Blood samples from the mothers and the newborn infant monkeys were collected within 12 h after parturition.

**Western blotting.** SRV-specific Abs were assessed by Western blotting using SRV-T.<sup>5</sup> Purified virus for this analysis was obtained from the culture supernatant of cloned SRV-T-infected A549 cells by ultracentrifugation through a sucrose gradient; purified viruses were disrupted by 1% SDS for use as antigen in Western blotting. The criterion for a positive reaction was detection of 2 or more virion-specific bands (that is, Gag and Env proteins).

**RT-PCR.** RNA was extracted from serum of the monkeys (QIAamp Viral RNA Mini Kit, Qiagen, Tokyo, Japan, or MagNA Pure Compact Nucleic Acid Isolation Kit I, Roche, Mannheim,

Received: 31 Jul 2009. Revision requested: 05 Sep 2009. Accepted: 11 Oct 2009.

<sup>1</sup>The Corporation for Production and Research of Laboratory Primates and <sup>2</sup>Tsukuba Primate Research Center (TPRC), National Institute of Biomedical Innovation, Tsukuba, Japan.

\*Corresponding author. Email: fujimoto@primate.or.jp

Germany). Reverse transcription was performed (ThermoScript RT-PCR System, Invitrogen, Tokyo, Japan) by using gene-specific reverse primers. PCR analysis was performed (Premix ExTaq Hot-Start Version, Takara, Shiga, Japan) by using published sets of external primers (SRVenv1E and SRVenv2E) and nested primers (SRVenv3N and SRVenv4N).<sup>9</sup>

## Results

**SRV infection status of the 419 laboratory-bred breeders.** Of the 419 (female, 364; male, 55) cynomolgus macaques evaluated, 22 were negative for both SRV-specific antibodies and RNA. Of the remaining 397 breeders, 340 were positive for SRV-specific antibodies but were not viremic, 29 were positive for both viral RNA and antibodies, and the remaining 28 monkeys had viremia without antibodies.

**SRV infection status of 95 pairs of mothers and offspring at birth.** RT-PCR and Western blotting of samples from 95 pairs of mothers and offspring at the time of birth revealed that the dams could be grouped into 1 of 3 categories based on the presence of SRV-specific antibodies and viremia.<sup>2</sup> Among the 95 dams, 76 developed SRV-specific Abs without viremia, 14 had both antibodies and viremia, and the remaining 5 were viremic without SRV-specific antibodies.

None of the offspring of the 76 dams that were antibody-positive but RNA-negative were viremic at birth. Eight infants (including 2 delivered by caesarian section) of the 14 dually positive dams were viremic at birth; the remaining 6 infants of dams in this group were viral RNA-negative. All 5 progeny (including 2 infants delivered by caesarian section) of viremic but antibody-negative dams were viremic at birth.

**Plasma SRV-specific antibodies and RNA in viremic newborns during the first 6 mo.** We then tested the SRV-specific antibody and RNA status of 3 representative viremic newborns at 1, 2, and 6 mo after birth (Table 1). All 3 of the dams exhibited SRV viremia at delivery, and 2 of them also were positive for SRV-specific antibodies. All 3 infants exhibited SRV-specific RNA at all time points, but none was antibody-positive at weaning.

**Family analysis of two representative SRV-viremic dams.** The SRV status of all 7 offspring born to 2 representative viremic mothers was verified in 2007. Dam 1319711082 and her 4 offspring (infant 1410311011, born 2003; infant 1420506016, born 2005; infant 1420608031, born 2006; and infant 1420709050, born 2007) all demonstrated SRV RNA in tests performed during 2007. In addition, this dam and her oldest infant (1410311011) were antibody-positive, unlike the 3 youngest siblings. Dam 1319710076 and her 3 offspring (infant 1410408017, born 2004; infant 1410508022, born 2005; and infant 1420701001, born 2007) were all RNA-positive but antibody-negative according to tests performed in 2007.

## Discussion

In 2005, we reported that about 20% of the cynomolgus monkeys in the colony at our institution exhibited SRV-T viremia and that virus was present in saliva, urine, and feces from the viremic monkeys.<sup>3-5</sup> Because the virus secreted from these monkeys was a potential source of horizontal SRV-T infection, we performed the current large-scale survey of SRV infections in our laboratory-bred monkeys and assessed the transmission of SRV through the generations represented in the colony.

The present study validated our concerns about vertical and horizontal SRV infections in the colony, because more than 90% of the laboratory-born breeders were positive for SRV-specific antibodies or virus (or both). The rate of viremia in the present study (14%) was smaller than that (20%) in the earlier survey,<sup>5</sup> which involved 49 retired breeders. The rate of viremia in a colony may vary depending on the age distribution of animals and their countries of origin. In particular, we hypothesize that the 28 monkeys that exhibited SRV viremia without specific antibodies are immunotolerant to SRV because of being infected in utero, as is reported to occur in rhesus and pigtailed macaques.<sup>7,12</sup>

To evaluate transplacental maternal-infant transmission of SRV, we tested 95 pairs of mothers and newborns, including 4 infants delivered by caesarian section, by using SRV-specific RT-PCR. The results showed that all monkeys exhibiting SRV-specific antibodies without viremia produced newborns without viremia. However, the transplacental SRV infections observed in infants included 4 newborns delivered by caesarian section from viremic mothers. In pigtailed monkeys, SRV2 was detected in the tissues and amniotic fluid of fetuses and in the blood of newborns delivered from viremic mothers.<sup>12</sup> In other cynomolgus monkeys, SRV was transmitted through transfusion of blood from a viremic donor but not from a nonviremic donor.<sup>13</sup> These findings indicate that SRV viremia of the mother is essential to establishing transplacental infection of the fetus. However, the production of 6 SRV-negative newborns from 14 viremic dams with SRV-specific antibodies may indicate that these antibodies reduced the viral loads in the viremic mothers sufficiently to prevent transplacental infection with SRV. Further investigation to quantify SRV in blood and the occurrence of transplacental infections will resolve this question.

An important issue is whether SRV viremic newborns can convert to a nonviremic state after developing virus-specific antibodies. Three infants born from viremic mothers exhibited viremia, which was maintained at 1, 2, and 6 mo of age, with no antibodies at 6 mo of age. In addition, 7 offspring born from the representative 2 SRV-viremic mothers were all viremic, at ages of 6 mo to 4 y. Pigtailed monkey newborns infected transplacentally with SRV2 maintained a viremic state for 1 y without producing antibodies and harbored proviral DNA in many tissues.<sup>11,12</sup> A newborn rhesus monkey produced from a viremic mother was SRV1-positive within 24 h after birth and was antibody-negative for as long as 6 mo after birth.<sup>7</sup> These findings suggest that cynomolgus infants infected in utero with SRV and born from viremic mothers are immunologically tolerant to the virus and that they then become the source of SRV infection in the colony.

The cynomolgus monkey breeding colony at our institution has been maintained as SPF with regard to B virus, SVV, SIV, STL1, and measles virus but not SRV. The cage system used during the first 25 y was a two-story type—monkeys were able to touch feces and urine of animals in adjacent cages. In addition, cages were washed with high-pressure water, perhaps helping to spread virus-contaminated waste and increasing the likelihood of horizontal infections. After redesigning the cage system to a single-story type that prevents monkeys from touching fecal and urine waste from another macaque, we anticipate that we will be able to establish an SRV-free colony by introducing SRV nonviremic monkeys into the breeding colony. Furthermore, elimination of viremic dams, which can become a source of transplacental infection, from the breeding colony is critical to establishing an

**Table 1.** SRV-specific antibodies and RNA in the plasma of viremic newborns during their first 6 mo

Infant ID	Method of delivery	Dam ID	Method of nursing	Status of dam at parturition		Status of infant at				
				Antibodies	RNA	0 d	1 mo	2 mo	Weaning (approximately 6 mo)	
						RNA	RNA	RNA	Antibodies	RNA
1310611144	Caesarean	1210003019	Artificial	+	+	+	+	+	-	+
1410508022	Natural	1319710076	Artificial	-	+	+	+	+	-	+
1420506016	Natural	1319711082	Maternal	+	+	+	+	+	-	+

Testing of infants for SRV-specific antibodies was delayed until weaning because transplacentally transferred maternal antibodies can persist at 2 mo of age.

SRV-free breeding colony. The establishment of an SRV-free cynomolgus breeding colony is paramount for supplying monkeys that are appropriate for many fields of investigation, including vaccine testing, gene therapeutics, organ transplantation, and infectious disease studies.

### Acknowledgment

This work was supported by a grant from the Ministry of Health, Labor, and Welfare of Japan.

### References

- Daniel MD, King NW, Letvin NL, Hunt RD, Sehgal PK, Desrosiers RC. 1984. A new type D retrovirus isolated from macaques with an immunodeficiency syndrome. *Science* 223:602-605.
- Guzman RE, Kerlin RL, Zimmerman TE. 1999. Histologic lesions in cynomolgus monkeys (*Macaca fascicularis*) naturally infected with simian retrovirus type D: comparison of seropositive, virus-positive, and uninfected animals. *Toxicol Pathol* 27:672-677.
- Hara M, Sato T, Kikuchi T, Nakajima N, Uda A, Fujimoto K, Baba T, Mukai R. 2005. Isolation and characterization of new simian retrovirus type D subtype from monkeys at the Tsukuba Primate Center, Japan. *Microbes Infect* 7:126-131.
- Hara M, Kikuchi T, Ono F, Takano J, Ageyama N, Fujimoto K, Terao K, Baba T, Mukai R. 2005. Survey of captive cynomolgus macaques colonies for SRV/D infection using polymerase chain reaction assays. *Comp Med* 55:145-149.
- Hara M, Kikuchi T, Sata T, Nakajima N, Ami Y, Sato Y, Tanaka K, Narita T, Ono F, Akari H, Terao K, Mukai R. 2007. Detection of SRV/D shedding in body fluids of cynomolgus macaques and comparison of partial gp70 sequences in SRV/D-T isolate. *Virus Genes* 35:281-288.
- Lerche NW, Osborn KG, Marx PA, Prahalada S, Maul DH, Lowenstine LJ, Munn RJ, Bryant ML, Henrickson RV, Arthur LO, Gilden RV, Barker CS, Hunter E, Gardner MB. 1986. Inapparent carriers of simian acquired immune deficiency syndrome type D retrovirus and disease transmission with saliva. *J Natl Cancer Inst* 77:489-496.
- Lerche NW, Marx PA, Osborn KG, Maul DH, Lowenstine LJ, Bleviss ML, Moody P, Henrickson RV, Gardner MB. 1987. Natural history of endemic Type D retrovirus infection and acquired immune deficiency syndrome in group-housed rhesus monkeys. *J Natl Cancer Inst* 79:847-854.
- Lerche NW, Yee JL, Jennings MB. 1994. Establishing specific retrovirus-free breeding colonies of macaques: an approach to primary screening and surveillance. *Lab Anim Sci* 44:217-221.
- Liska V, Lerche NW, Ruprecht RM. 1997. Simultaneous detection of simian retrovirus type D serotype 1, 2 and 3 by polymerase chain reaction. *AIDS Res Hum Retroviruses* 13:433-437.
- Marx PA, Maul DH, Osborn KG, Lerche NW, Moody P, Lowenstine LJ, Henrickson RV, Arthur LO, Gilden RV, Gravell M, London WT, Sever JL, Levy JA, Munn RJ, Gardner MB. 1984. Simian AIDS: isolation of a type D retrovirus and transmission of the diseases. *Science* 223:1083-1086.
- Moazed TC, Thouless ME. 1993. Viral persistence of simian type D retrovirus (SRV2/W) in naturally infected pigtailed macaques (*Macaca nemestrina*). *J Med Primatol* 22:382-389.
- Tsai CC, Follis KE, Snyder K, Windsor S, Thouless ME, Kuller L, Morton WR. 1990. Maternal transmission of type D simian retrovirus (SRV/D) in pregnant macaques. *J Med Primatol* 19:203-216.
- Wilkinson RC, Murrell CK, Guy R, Davis G, Hall JM, North DC, Rose NJ, Almond N. 2003. Persistence and dissemination of simian retrovirus type 2 DNA in relation to viremia, seroresponse, and experimental transmissibility in *Macaca fascicularis*. *J Virol* 77:10751-10759.

Transgenic Research  
Associated with the International Society for Transgenic Technologies  
(ISTT)

© Springer Science+Business Media B.V. 2010

10.1007/s11248-009-9358-9

## Brief Communication

# Preferential expression and immunogenicity of HIV-1 Tat fusion protein expressed in tomato plant

Marni E. Cueno<sup>1</sup>, Yurina Hibi<sup>1</sup>, Katsuo Karamatsu<sup>2</sup>, Yasuhiro Yasutomi<sup>2</sup>, Kenichi Imai<sup>1</sup>, Antonio C. Laurena<sup>3</sup> and Takashi Okamoto<sup>1</sup> 

- (1) Department of Molecular and Cellular Biology, Molecular and Cellular Biology Laboratory, Graduate School of Medical Sciences, Nagoya City University, 1 Kawasumi, Misuho-cho, Mizuho-ku, Nagoya Aichi, 467-8601, Japan
- (2) Laboratory of Immunoregulation and Vaccine Research, Tsukuba Primate Research Center, National Institute of Biomedical Innovation, Tsukuba Ibaraki, 305-0843, Japan
- (3) Biochemistry Laboratory, Institute of Plant Breeding, University of the Philippines Los Banos, Laguna, 4031, Philippines

 **Takashi Okamoto**

**Email:** [tokamoto@med.nagoya-cu.ac.jp](mailto:tokamoto@med.nagoya-cu.ac.jp)

**Received:** 11 June 2009 **Accepted:** 26 December 2009 **Published online:** 14 January 2010

**Abstract** HIV-1 Tat plays a major role in viral replication and is essential for AIDS development making it an ideal vaccine target providing that both humoral and cellular immune responses are induced. Plant-based antigen production, due to its cheaper cost, appears ideal for vaccine production. In this study, we created a plant-optimized tat and mutant (Cys30Ala/Lys41Ala) tat (mtat) gene and ligated each into a pBI121 expression vector with a stop codon and a gusA gene positioned immediately downstream. The vector construct was bombarded into tomato leaf calli and allowed to develop. We thus generated recombinant tomato plants preferentially expressing a Tat-GUS fusion protein over a Tat-only protein. In addition, plants bombarded with either tat or mtat genes showed no phenotypic difference and produced 2–4  $\mu$ g Tat-GUS fusion protein per milligram soluble plant protein. Furthermore, tomato extracts intradermally inoculated into mice

were found to induce a humoral and, most importantly, cellular immunity.

Keywords AIDS - Antibody response - Cellular immune response - HIV-1 - Tat - Transgenic tomato

---

## Introduction

HIV-1 has already claimed millions of victims worldwide and despite billions of dollars spent on HIV-1/AIDS research annually (Walker and Burton [2008](#); Watkins et al. [2008](#)), no promising candidate HIV-1 vaccine has been made to date due to: (a) specific viral characteristics including extreme genetic variability among various isolates collected worldwide and even within the infected individuals; (b) a high mutation rate allowing rapid escape of variants from immune responses; and (c) biological properties of HIV-1 regulatory proteins, such as Nef and Tat, which avoid immune responses (Walker and Burton [2008](#); Watkins et al. [2008](#); WHO [2008](#); Potts et al. [2008](#)). As widely believed, these characteristics pose a major obstacle towards controlling AIDS (Gaschen et al. [2002](#); Moore et al. [2008](#)).

An ideal strategy against HIV-1 is one that stimulates passive protection or neutralizing immunity by producing both antibodies and cytotoxic T lymphocytes or CTLs (Walker and Burton [2008](#); Watkins et al. [2008](#); Addo et al. [2001](#)). Earlier works have shown that CTLs can control HIV-1 replication in the absence of antibodies (Borrow et al. [1994](#)) prompting several attempts to stimulate anti-viral CTL responses using a combination of varying HIV-1 proteins and their epitopes (Betts et al. [2005](#); Matano et al. [2004](#); Mwau et al. [2004](#)). The Tat protein has been one of the well studied HIV-1 proteins (Barboric and Peterlin [2005](#); Emerman and Malim [1998](#); Goldstein et al. [2001](#); Okamoto and Wong-Staal [1986](#); Ramirez et al. [2007](#)). It is a small regulatory protein composed of either 86 or 101 amino acid residues (14 or 18 kDa, respectively) encoded by two exons (Okamoto [1995](#)). Among the HIV-1 proteins already studied, Tat shows great potential for CTL induction covering a wide variety of HIV-1 clones besides from little variability among distinct viral subtypes and is highly conserved in both inter- and intra-patient variants (Addo et al. [2001](#); Goldstein et al. [2001](#)).

Over 4 million people become infected with HIV-1 each year (WHO [2008](#); Fox [2007](#)) in third-world countries in particular (Flexner [2008](#)). Cheap and affordable production of pharmaceutical products for third-world consumption has prompted the development of plant-made pharmaceuticals for often neglected diseases (Zahn et al. [2008](#)), including HIV-1 (Ramirez et al. [2007](#); Flexner [2008](#);

Shchelkunov et al. 2006; Webster et al. 2005). Previous attempts to utilize the tomato plant for HIV-1 Tat vaccine development in the form of an edible-vaccine was only successful in inducing antibodies or humoral immune response (Ramirez et al. 2007; Shchelkunov et al. 2006). At present, no report has been made with regards to induction of CTLs or cellular immune responses using Tat protein (Addo et al. 2001), more so, using a plant-expressed Tat protein.


In this study, we demonstrate the evidence of preferential expression of a Tat-GUS fusion protein over the Tat-only protein in tomato plant and is expressed much higher than previously reported (Ramirez et al. 2007). In addition, we were able to induce both humoral immune response and, surprisingly, cellular immune response using Balb/c mice when tomato extracts were intradermally introduced. To our knowledge, this is the first report of cellular immune induction using Tat expressed in a plant system.

---

## Materials and methods

### Vector construction and tomato transformation

The tat gene from the HXB2 strain of HIV-1 and mtat were synthesized following a specific codon-usage table based on tomato was used ([www.kazusa.or.jp/codon/cgi-bin/showcodon.cgi?species=4081](http://www.kazusa.or.jp/codon/cgi-bin/showcodon.cgi?species=4081)). The plant-optimized M2 epitope directly fused to either tat or inactive mtat (Imai et al. 2005) genes with a stop codon, were individually ligated into a pBI121 expression vector (Clontech) upstream of a gusA gene (Fig. 1). Transformation was performed using a particle gun (Tanaka Co., Ltd, Tokyo, Japan) and the tomato var. Improved Pope as previously published (Bhatia and Ashwath 2004; Sheeja et al. 2004). Briefly, the sterilized seeds were grown in MS medium and allowed to grow for 7–10 days. Callus induction of the explant material was performed in a MS medium containing 1.0 ppm zeatin for 7 days. Bombardment was carried out in tomato calli grown in MS medium containing 0.5 ppm zeatin, 1.0 ppm indole-butyric acid and 1.0 ppm giberillic acid. All reagents used for tomato transformation were purchased from Sigma.



**Fig. 1** Construction of the pBI121 plant expression vector containing either *tat* or *mtat* indirectly fused to *gusA* gene. **a** Expression was driven by 35S CaMV promoter and terminated with NOS termination signal located downstream of *gusA* gene. The inserted *tat/mtat* gene is located upstream of the *gusA* gene containing the termination codon (TAA) in between. **b** Codon-optimized *tat* and *mtat* were synthesized following the codon usage of tomato. The boxed regions represent point mutations at Cys30Ala and Lys41Ala found in *mtat* [23]. The underlined segment represents M2 epitope added to serve as an expression tag. Wt-Tat represents the Tat sequence from the HXB2 strain. Tm-Tat and Tm-mTat represents codon-optimized tomato Tat and mTat, respectively

## Reverse transcription-PCR

Triplicates of bombarded tomato calli, regenerated leaf and shoot tissues were freshly obtained for mRNA extraction. The MicroFastTrack™ 2.0 mRNA Isolation Kit (Invitrogen) was used to isolate mRNA according to manufacturer's instructions. The Cloned AMV First-Strand cDNA Synthesis Kit (Invitrogen) was used to synthesize cDNA according to manufacturer's instructions. The forward primer, TAT-F (5' -ATG GAA CCA GTT GAT CC-3'), used was based on the tomato codon-based HIV-1 *tat*, whereas, the reverse primer, GUS-R (5' -CGG TAT AAA GAC TTC GCG CTG-3') was based on *gusA*. Both primers were synthesized by Invitrogen. The TOUCHDOWN PCR condition was performed using the TaKaRa Taq™ Hot Start Version (Takara Bio Inc., Japan) with an initial denaturation temperature of 95° C for 5 min proceeded by 5 cycles of 94° C for 1 min, 55° C for 1 min and 72° C for 2 min. This was followed by another 5 cycles of 94° C for 1 min, 53° C for 1 min and 72° C for 2 min. The last set of cycles consists of 25 cycles at 94° C for 1 min, 50° C for 1 min and 72° C for 2 min. A final 10 min extension at 72° C was also performed. Reverse transcription-PCR (RT-PCR) products were resolved on 1% agarose gel.

## Protein extraction

Protein extracts were obtained from 2-weeks old transgenic tomato plants. Protein extraction was done on all transgenic samples using the P-PER Plant Protein Extraction Kit (Thermo Scientific) according to manufacturer's recommendation. Tomato protein extracts acquired ( $\sim 100 \mu\text{l}$ ) were divided for use in Western blot assay and Immunogenicity testing.

## Western blot assay

Western blot using both antibodies against Tat and M2 (Sigma) was performed and amount of Tat expressed in bombarded tomato plants were estimated using the Bio-Dot Microfiltration Apparatus (BIO-RAD) as previously published (Ota et al. 2005). The Tat protein standard used was a recombinant Tat (ImmunoDiagnostics, Inc.) with various dilutions.

## Immunogenicity testing


Balb/c mice were intradermally immunized with the recombinant tomato protein extracts mixed in an incomplete Freund's adjuvant (IFA). The peptides used in this study were the Tat CTL epitope (Morris et al. 2001) and B cell epitope (Goldstein et al. 2001). Tat-specific antibody responses were measured by ELISA. Briefly, synthetic peptides for Tat and mutant Tat (mTat) diluted in PBS were coated in multiwell plates overnight at  $4^\circ\text{C}$  followed by 30 min of blocking with non-fat milk. Test samples were then added and incubated at room temperature for 1 h. After washing, the reacted antibodies were detected using the HRPO-labeled goat anti-mouse IgG (H + L) and ABTS substrate (Roche Diagnostics). The  $\text{OD}_{405}$  was recorded and used as a relative measure of antibody titer.


The number of Tat-specific IFN- $\gamma$  secreting cells indicating specific CTL activity was determined by ELISPOT assay (Takamura et al. 2005). Briefly, a 96-well nitrocellulose plate (Millipore Corporation) was coated with anti-mouse IFN- $\gamma$  mAb R4-6A2 (Phermigen) and incubated at  $4^\circ\text{C}$  overnight. After washing with PBS, complete medium with 10% fetal calf serum was added and incubated at  $37^\circ\text{C}$  for 1 h. Triplicate samples of  $\text{CD8}^+$  T cells separated from the spleen of the immunized mice were plated in two-fold dilutions from  $5 \times 10^5$  to  $6.25 \times 10^4$  cells/well [29], added with Tat CTL peptide and incubated for 24 h at  $37^\circ\text{C}$  in 5%  $\text{CO}_2$ . After washing with PBS-T, biotinylated anti-mouse IFN- $\gamma$  mAb XMG1.2 (Phermigen) was added and incubated overnight at  $4^\circ\text{C}$ . Plates washed with PBS-T were added with streptavidin-conjugated alkaline phosphatase (AP) (Mabtech AB) and visualized using AP color development buffer (BIO-RAD) and counted by KS ELISPOT (Carl Zeiss, Inc.).

## Results and discussion

### Preferential expression of mTat/Tat-GUS fusion protein in tomato plant

Comparison between the control and transgenic tomato lines (Fig. 2a) showed that the transgenic lines were stunted in growth compared to the control tomato lines consistent with Tat expression (Ramirez et al. 2007; Karasev et al. 2005). Among 82 total calli bombarded (with either Tat or mTat), 55 (67.1%) survived with 14 (25.5%) confirmed plant regeneration. To confirm transformation, tomato extracts were used for Western blot analysis using anti-Tat and anti-M2 antibodies. A ~40 kDa protein, representing the mTat/Tat-GUS fusion protein (mTat/Tat is 14 kDa in size and GUS is 26 kDa in size), was detected instead of the expected 14 kDa size representing an mTat/Tat-only protein (Fig. 2b, c).






**Fig. 2** Expression of both Tat and mTat proteins in tomato plant using particle-gun bombardment. **a** All tomato calli bombarded followed the same bombardment conditions and grown for 3 weeks. Control samples were bombarded with pBI121 vector only. Tat and mTat samples were bombarded with Tat- and mTat-pBI121 vectors, respectively. **b** Western blot assay using tomato extracts from the bombarded samples and detected with anti-Tat and anti-M2 antibodies as indicated in the *bottom*. Only a 40 kDa protein was clearly detected from either Tat- and mTat-pBI121 bombarded tomatoes representing a mTat/Tat-GUS fusion proteins. No 14 kDa protein was detected. **c** Schematic illustration of expected (Tat-only) and actual (Tat-fusion) protein transiently expressed. **d** Reverse transcription-PCR was performed using cDNA obtained from both Tat- and mTat-bombarded callus (Ca), shoot (Sh) and leaf (Le) tissues. Likewise, cDNA obtained from pBI121-bombarded tomato were used as controls. **e** Dot-blot assay providing estimated amounts of Tat expressed in both Tat- and mTat-bombarded tomato plants

The indirect fusion between *mtat/tat* and *gusA* genes was designed to allow the tomato plant to selectively express either a fusion protein, a single protein or both. As seen in Fig. 2b, Tat and mTat were successfully expressed in all tomato extracts but only as a fusion protein and regardless of the stop codon found downstream of the *tat* gene which would have allowed a Tat-only protein to be expressed. Figure 2c illustrates the expected (Tat-only) and actual (Tat-fusion) proteins detected in the transgenic tomato lines. Expression of a fusion protein is suggestive of a codon read-through event (Tork et al. 2004) implying preferential expression of the fusion protein over the Tat-only protein in tomato plants. To resolve the transgenic nature of the Tat- and mTat-bombarded tomato calli, RT-PCR was performed. Figure 2d confirms the active transcription and presence of *mtat/tat* mRNA in all three sets of the transgenic tomato callus, shoot and leaf. In addition, since we were able to amplify a PCR product using a forward primer based on the *tat* gene and a reverse primer based on the *gusA* gene, we show that

a *tat-gusA* mRNA is transcribed further confirming production of Tat-GUS fusion protein. Furthermore, tomato extracts were found to contain  $\sim 2\text{--}4 \mu\text{g}$  mTat/Tat-GUS fusion protein per milligram plant protein (Fig. 2e) much higher than previous attempts (Ramirez et al. 2007; Karasev et al. 2005). This would imply that in tomato, Tat-GUS fusion protein is the protein form preferentially expressed allowing for a higher amount of protein production. Though the reason that drives the tomato plant to preferentially express the fusion protein is unclear, the significance of both the fusion protein and the amount produced in tomato plant was tested for its immunogenicity by injecting the tomato extracts into Balb/c mice.


## Induction of antibody and CTL in Balb/c mice using recombinant tomato extracts

To test the immunogenicity of the fusion protein, Balb/c mice were intradermally injected with the recombinant tomato protein extracts and checked for immunogenic responses. Considering, previous attempts using a Tat-only protein have, thus far, successfully induced a humoral immune response (Ramirez et al. 2007; Karasev et al. 2005), we first established the consistency of humoral immune induction using Tat, in fusion form, in Balb/c mice. Humoral IgG immune responses were detected in the range of 1:10–1:160 titers before leveling-off at 1:320 for both mTat- and Tat-bombarded extracts (Fig. 3). The tomato extracts were found to induce a humoral immune response, regardless of the nominal amount used, and showed that Tat in fusion form could still induce an antibody response consistently with previous works using Tat-only protein (Ramirez et al. 2007; Karasev et al. 2005).



**Fig. 3** Induction of IgG humoral immune response in Balb/c mice by recombinant tomato extracts. Plant extracts containing 5  $\mu$ g Tat were inoculated in five mice intradermally. After 2 weeks, these mice were bled and the anti-Tat IgG antibody titer was measured by ELISA. The figures represent the mean and standard deviation of anti-Tat antibody response but the standard deviations could not be seen because of very small differences. Normal tomato extracts were used as control

Interestingly, a cellular immune response, though minimal, was also detected. Cellular immune responses as detected by IFN- $\gamma$  production were modestly induced at 22–24 cells/ $1 \times 10^6$  splenocytes using the recombinant tomato protein extracts (Fig. 4). It is noteworthy that Balb/c mice are normally used to test Th2 immune responses which are known to inhibit macrophage activation and instead stimulate antibody production (Mills et al. 2000), explaining the relatively low IFN- $\gamma$  produced using our tomato extracts. Nevertheless, of greater importance is the ability of Tat protein, in fusion form, to induce a CTL response. The vaccine potential of utilizing HIV-1 Tat relies heavily in its ability to induce both humoral and cellular immunity in the host. Given that both IFN- $\gamma$  and IgG were detected from the same induced Balb/c mice, it was clearly demonstrated that a Tat-GUS fusion protein was preferentially expressed over the Tat-only protein in tomato plants. Furthermore, Tat in fusion form would seem to be ideal in inducing both humoral and cellular immune responses which coincidentally are the requirements of a model HIV-1 vaccine (Walker and Burton 2008; Gaschen et al. 2002; Borrow et al. 1994). To our knowledge, this is the first report of induction of anti-Tat cellular immunity in Balb/c mice, using Tat protein in fusion form expressed in tomato plant.



**Fig. 4** Induction of cellular immune response in Balb/c mice by recombinant tomato extracts. IFN- $\gamma$  secreting cells were determined by ELISPOT assay. CD8<sup>+</sup> cells were prepared from the spleen of each mouse and approximately  $5\text{--}6.25 \times 10^4$  cells per well were incubated with the synthetic Tat

peptide (Tat17-25) for 24 h, plates were washed by PBS-T, further incubated overnight at 4°C in the presence of 2  $\mu$ g/ml of biotinylated anti-mouse IFN- $\gamma$  monoclonal antibody, and the number of IFN- $\gamma$  secreting CD8<sup>+</sup> T cells were visualized by adding streptavidin conjugated alkaline phosphatases. Data represent the mean and standard deviation of three independent experiments

---

## No significant difference between wild-type and mutant Tat expressed in tomato plant


It is worth mentioning that tomato plants bombarded with either mtat or tat gene are both stunted in growth (Fig. 2a) and found to have no significant difference (Fig. 2b, c) implying that the mutations found in mTat are insufficient to distinguish it from Tat when expressed in tomato. With regards to immunogenicity, although previous findings (Kanazawa et al. 2000; Okamoto et al. 2000; Lilen et al. 2002) suggested that wild-type Tat might inhibit immune responses by downregulating the function of antigen presenting cells, the extent of immune responses elicited by either Tat or mTat did not apparently show any difference in mice. This is perhaps because murine Cyclin T1 does not bind to HIV-1 Tat (Bieniasz et al. 1998). Thus, a similar study using primates is warranted since, in human and primate cells, we expect a lower immunogenicity for Tat compared to mTat because of the recruitment of Cyclin T1 that is required for the action of class II transactivator expressing class II MHC molecules (Kanazawa et al. 2000; Okamoto et al. 2000; Lilen et al. 2002).

**Acknowledgments** We thank Professor Masahiro Sugiura for helpful comments and encouragement throughout the study. This work was supported by grants-in-aid from Ministry of Health, Labor and Welfare, Japan, and Ministry of Culture, Science and Technology, Japan. The anti-Tat reagent was obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 Tat Monoclonal (7D5.1) from Dr. Jonathan Karn.

---

## References


Addo MM, Altfeld M, Rosenberg ES, Eldridge RL, Philips MN, Habeeb K, Khatri A et al (2001) The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals. *Proc Natl Acad Sci USA* 98:1781–1786




Barboric M, Peterlin BM (2005) A new paradigm in eukaryotic biology: HIV Tat and the control of transcriptional elongation. *PLoS Biol* 3:200–203



Betts MR, Exley B, Price DA, Bansal A, Camacho ZT, Teaberry V, West SM et al (2005) Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection. *Proc Natl Acad Sci USA* 102:4512–4517




Bhatia P, Ashwath N (2004) Comparative performance of micropropagated and seed-grown tomato plants. *Biologia Plantarum* 48:625–628




Bieniasz PD, Grdina TA, Bogerd HP, Cullen BR (1998) Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat. *EMBO* 17:7056–7065



Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MBA (1994) Virus-specific CD8<sup>+</sup> cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. *J Virol* 68:6103–6110



Emerman M, Malim MH (1998) HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology. *Science* 280:1880–1884




Flexner C (2008) HIV drug development: the next 25 years. *Nat Biotech* 26(Suppl):s39–s46


Fox JL (2007) Antivirals become a broader enterprise. *Nat Biotech* 25:1395–1402




Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D, Novitsky V et al (2002) Diversity considerations in HIV-1 vaccine selection. *Science* 296:2354–2360




Goldstein G, Tribbick G, Manson K (2001) Two B cell epitopes of HIV-1 Tat proteins have limited antigenic polymorphism in geographically diverse HIV-1 strains. *Vaccine* 19:1738–1746




Imai K, Nakatawa K, Kawai K, Hamano T, Mei N, Kasai H, Okamoto T (2005) Induction of OGG1 gene expression by HIV-1 Tat. *J Biol Chem* 280:26701–26713



Kanazawa S, Okamoto T, Peterlin BM (2000) Tat competes with CIITA for the binding to P-TEFb and blocks the expression of MHC class II genes in HIV infection. *Immunity* 12:61–70




Karasev AV, Foulke S, Wellens C, Rich A, Shon KJ, Zwierzynski I, Hone D et al (2005) Plant-based HIV-1 vaccine candidate: Tat protein produced in spinach. *Vaccine* 23:1875–1880




Lilen SC, Imai K, Asamitsu K, Toshifumi T, Barzaga N, Okamoto T (2002) Inhibitory effects of IFN- $\gamma$  on HIV-1 replication in latently infected cells. *Biochem Biophys Res Commun* 291:890–896



Matano T, Kobayashi M, Igarashi H, Takeda A, Nakamura H, Kano M, Sugimoto C et al (2004) Cytotoxic T lymphocytes-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. *J Exp Med* 199:1709–1718




Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM (2000) M-1/M-2 macrophages and the Th1/Th2 paradigm. *J Immunol* 164:6166–6173




Moore JP, Klasse PJ, Dolan MJ, Ahuja SK (2008) A step into darkness or light? *Science* 320:753–755



Morris CB, Thanawastien A, Sullivan DE, Clements JD (2001) Identification of a peptide capable of inducing an HIV-1 Tat specific CTL response. *Vaccine* 20:12–15




Mwau M, Ceberé I, Sutton J, Chikoti P, Winstone N, Wee EGT, Beatie T et al (2004) A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. *J Gen Virol* 85:911–919




Okamoto T (1995) Regulatory proteins of human immunodeficiency virus and therapy. In: Mohan P, Baba M (eds) *Anti-AIDS development: challenges, strategies and prospects*. Harwood Academic Publishers, Singapore, pp 117–123


Okamoto T, Wong-Staal F (1986) Demonstration of virus-specific transcriptional activator(s) in cells infected with HTLV-III by an in vitro cell-free system. *Cell* 47:29–35




Okamoto H, Asamitsu K, Nishimura H, Kamatani N, Okamoto T (2000) Reciprocal modulation of transcriptional activities between HIV-1 Tat and MHC class II transactivator CIITA. *Biochem Biophys Res Commun* 279:494–499



Ota S, Kanazawa S, Kobayashi M, Otsuka T, Okamoto T (2005) Establishment of a simple and quantitative immunospot assay for detecting anti-type II collagen antibody using infrared fluorescence imaging system (IFIS). *J Immunol Methods* 299:189–198



Potts M, Halperin DT, Kirby D, Swidler A, Marseille E, Klausner JD, Hearst N et al (2008) Reassessing HIV prevention. *Science* 320:749–750



Ramirez YJP, Tasciotti E, Gutierrez-Ortega A, Donayre AJ, Flores MTO, Giacca M, Lim MAG (2007) Fruit-specific expression of the human immunodeficiency virus type 1 Tat gene in tomato plants and its immunogenic potential in mice. *Clin Vaccine Immunol* 14:685–692



Shchelkunov SN, Salyaev RK, Pozdnyakov SG, Rekoslavskaya NI, Nesterov AE, Ryzhova TS, Sumstova VM et al (2006) Immunogenicity of a novel bivalent, plant-based oral vaccine against hepatitis B and human immunodeficiency viruses. *Biotechnol Lett* 28:959–967




Sheeja TE, Mondal AB, Rathore RKS (2004) Efficient plantlet regeneration in tomato (*Lycopersicon esculentum* Mill.). *Plant Tissue Cult* 14:45–53


Takamura S, Matsuo K, Takebe Y, Yasutomi Y (2005) Ag85B of mycobacteria elicits effective CTL responses through activation of robust Th1 immunity as a novel adjuvant in DNA vaccine. *J Immunol* 175:2541–2547




Tork S, Hatin I, Rousset J-P, Fabret C (2004) The major 5' determinant in stop codon read-through involves two adjacent adenines. *Nucleic Acids Res* 32:415–421




Walker BD, Burton DR (2008) Toward and AIDS vaccine. *Science* 320:760–764



Watkins DI, Burton DR, Kallas EG, Moore JP, Koff WC (2008) Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. *Nat Med* 14:617–621



Webster DE, Thomas MC, Pickering R, Whyte A, Dry IB, Gorry PR, Wesselingh SL (2005) Is there a role for plant-made vaccines in the prevention of HIV/AIDS? *Immunol Cell Biol* 83:239–247



WHO (2008) Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report 2008. WHO Press, Spain

Zahn LM, Hines PJ, Pennisi E, Travis J (2008) Green genes. *Science* 320:465–478

